While individualized oncologic treatments are becoming a common practice, it is necessary to evaluate brain metastases (BM) management in a homogeneous primitive population. In patients with a limited number of BM from NSCLC, SRT is an effective treatment associated with high local control rate, low neurological deterioration, and with low morbidity. Close follow-up with MRI is mandatory to perform salvage treatment. Patients with BM from NSCLC should be included in randomized trials evaluating new systemic therapies, to monitor synergic effects (efficacy or toxicity), and to clarify the role of SRT in the global care of their BM. Read more.